Lyme Disease in Dogs: Borrelia burgdorferi Serological and Molecular Testing in Endemic Regions
Introduction
Lyme disease (Lyme borreliosis) in dogs is caused by infection with the spirochete bacterium Borrelia burgdorferi sensu lato, primarily transmitted through the bite of infected ixodid ticks. In North America, the principal vector is Ixodes scapularis (the black-legged tick or deer tick) in the northeastern, mid-Atlantic, and upper midwestern United States, and Ixodes pacificus (the western black-legged tick) along the Pacific coast [1, 2]. In Europe and Asia, Ixodes ricinus and Ixodes persulcatus serve as the primary vectors, with Borrelia afzelii and Borrelia garinii as the dominant genospecies [3, 4]. The clinical presentation in dogs differs markedly from that in humans; dogs rarely develop the erythema migrans rash or acute arthritis, and instead may present with fever, lethargy, lymphadenomegaly, and acute-onset lameness due to polyarthropathy [5, 6]. A small subset of dogs develops Lyme nephritis, a severe immune-complex-mediated glomerulonephritis with a poor prognosis [7, 8].
Accurate diagnosis in endemic regions is critical for appropriate clinical management and for differentiating infection from other tick-borne coinfections such as Anaplasma phagocytophilum, Ehrlichia canis, and Babesia species [9, 10]. This review provides an exhaustive examination of the serological and molecular diagnostic modalities available for B. burgdorferi detection in dogs, with a focus on the C6 antibody test versus polymerase chain reaction (PCR) for early infection, regional tick vector distributions, and vaccination recommendations.
Pathogen Biology and Host Immune Response
Borrelia burgdorferi is a motile, microaerophilic spirochete with a unique outer surface membrane containing numerous lipoproteins, including outer surface protein A (OspA), OspC, and the variable major protein-like sequence expressed (VlsE) antigen [11, 12]. The VlsE antigen undergoes antigenic variation through recombination at the vlsE locus, enabling immune evasion [13]. However, the invariable region 6 (IR6) of VlsE, known as the C6 peptide, is highly conserved across B. burgdorferi sensu lato genospecies and elicits a robust antibody response in infected dogs [14, 15].
Following tick inoculation, spirochetes migrate through the dermis and disseminate hematogenously to joints, kidneys, and other tissues [16]. The canine humoral immune response typically produces detectable IgM antibodies within 2 to 4 weeks post-infection, followed by IgG antibodies that persist for months to years [17]. The C6 antibody response is particularly durable and correlates with active infection, declining after successful antimicrobial therapy [18].
Serological Testing
Whole-Cell ELISA and Immunofluorescence Assays
Traditional serological methods include whole-cell enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence assay (IFA) using whole B. burgdorferi lysates [19]. These assays detect antibodies against multiple spirochetal antigens but suffer from cross-reactivity with other bacteria, including Leptospira species and oral treponemes, leading to false-positive results [20, 21]. Furthermore, whole-cell assays cannot distinguish between natural infection and vaccination-induced antibodies, limiting their utility in vaccinated populations [22].
C6 Peptide-Based ELISA
The development of the C6 peptide ELISA represented a significant advancement in canine Lyme serology. The C6 peptide corresponds to the IR6 region of VlsE and is not present in any commercial Lyme vaccines [23]. Therefore, a positive C6 antibody test indicates natural infection rather than vaccine exposure [24]. The C6 ELISA demonstrates high sensitivity (96-100%) and specificity (98-100%) for detecting B. burgdorferi infection in dogs [25, 26]. Antibodies to C6 appear as early as 3 to 5 weeks post-infection, coinciding with the onset of clinical signs in experimental models [27].
The quantitative C6 ELISA (quantitative C6 test) measures antibody levels in standardized units. Serial monitoring of C6 antibody concentrations can be used to assess treatment response; a significant decline (typically a 50% or greater reduction) in C6 antibody levels within 6 to 12 months of antibiotic therapy correlates with successful clearance of infection [28, 29]. Persistently elevated C6 levels may indicate ongoing infection or reinfection [30].
Western Blot (Immunoblot) Confirmation
Western blot (immunoblot) analysis is used as a confirmatory test following positive or equivocal ELISA results. The assay detects antibodies against specific B. burgdorferi proteins, including OspA, OspC, flagellin (41 kDa), and VlsE [31]. Interpretation criteria for canine immunoblots have been established, requiring reactivity to a minimum number of specific bands for a positive result [32]. Immunoblotting can differentiate between vaccination and natural infection by the presence of OspA antibodies (vaccine-associated) versus OspC and VlsE antibodies (infection-associated) [33]. However, immunoblotting is labor-intensive, subjective in band interpretation, and less commonly used in routine clinical practice compared to C6 ELISA.
Molecular Testing: Polymerase Chain Reaction
Polymerase chain reaction (PCR) detects B. burgdorferi DNA directly from clinical samples, offering the potential for early diagnosis before seroconversion [34]. Common target genes include the flagellin gene (flaB), the outer surface protein A gene (ospA), and the 16S ribosomal RNA gene [35, 36]. Real-time PCR (qPCR) provides quantitative data and higher sensitivity compared to conventional PCR [37].
Sample Types and Sensitivity
The choice of sample matrix critically affects PCR sensitivity. In experimentally infected dogs, blood PCR is positive only during the early spirochetemic phase, typically within the first 2 to 4 weeks post-infection, after which spirochetes are cleared from the bloodstream [38]. Synovial fluid, skin biopsies from tick bite sites, and renal tissue (post-mortem) yield higher sensitivity in later stages [39, 40]. In naturally infected dogs presenting with lameness, synovial fluid PCR has a reported sensitivity of 50-70%, while blood PCR sensitivity is less than 20% [41, 42]. Urine PCR has been evaluated but shows inconsistent results due to inhibitors and low bacterial load [43].
C6 Antibody Test versus PCR for Early Infection
For early detection of B. burgdorferi infection in dogs, the C6 antibody test and PCR have complementary roles. PCR can detect infection as early as 1 to 2 weeks post-tick attachment, preceding seroconversion by 1 to 3 weeks [44]. However, the narrow window of blood positivity limits its utility as a sole screening test. The C6 ELISA becomes positive by 3 to 5 weeks and remains positive for months, providing a wider diagnostic window [45].
In a comparative study of experimentally infected dogs, blood PCR was positive in 80% of dogs at 2 weeks post-infection but declined to 20% by 4 weeks, whereas C6 ELISA sensitivity reached 100% by 4 weeks [46]. For clinical decision-making in endemic regions, a negative blood PCR does not rule out infection, and serological testing is recommended as the primary screening tool. PCR is best reserved for cases with high clinical suspicion and negative serology, for testing synovial fluid in arthritic dogs, or for confirming infection in seropositive dogs with atypical presentations [47].
Regional Tick Vector Distributions
The geographic distribution of Ixodes vectors determines the endemicity of Lyme disease. In North America, I. scapularis is established across the northeastern and upper midwestern United States, with expanding populations into the southeastern states and southern Canada [48]. Ixodes pacificus is restricted to the Pacific coastal states, from California to Washington [49]. In Europe, I. ricinus is widespread from the British Isles through central and eastern Europe, while I. persulcatus dominates in Scandinavia, the Baltic region, and Russia [50]. Canine seroprevalence studies reflect these vector distributions, with prevalence rates exceeding 50% in some hyperendemic foci in the northeastern United States [51].
Vaccination Recommendations
Vaccination against B. burgdorferi is recommended for dogs residing in or traveling to endemic regions. Available vaccines include bacterin-based whole-cell vaccines and recombinant OspA vaccines [52]. OspA vaccines work by inducing antibodies in the dog that are ingested by the tick during feeding, neutralizing spirochetes within the tick midgut before transmission occurs [53]. Vaccination does not prevent infection but reduces the risk of clinical disease and decreases the bacterial load [54].
The C6 ELISA is unaffected by vaccination, allowing continued serological surveillance in vaccinated dogs [55]. Annual booster vaccination is recommended, and the decision to vaccinate should be based on risk assessment, including tick exposure history, geographic location, and lifestyle [56]. Concurrent tick control with acaricides is essential, as vaccination does not protect against other tick-borne pathogens.
Diagnostic Algorithm
The following Mermaid diagram illustrates a recommended diagnostic workflow for a dog with suspected Lyme disease in an endemic region.
flowchart TD
A[Clinical suspicion: lameness, fever, lymphadenopathy], > B{C6 ELISA}
B, >|Negative| C[Low probability of Lyme disease]
C, > D[Consider other tick-borne diseases: Anaplasma, Ehrlichia, Babesia]
B, >|Positive| E[Confirm with quantitative C6 or immunoblot if needed]
E, > F{Clinical signs present?}
F, >|Yes| G[Consider PCR on synovial fluid or blood]
G, > H[Positive PCR: confirm active infection]
G, > I[Negative PCR: does not rule out infection]
F, >|No| J[Subclinical infection: monitor C6 levels]
J, > K[Antibiotic therapy if high C6 or proteinuria]
H, > L[Initiate doxycycline therapy]
I, > L
L, > M[Recheck C6 in 6 months]
M, >|C6 decline >50%| N[Successful treatment]
M, >|C6 persistent| O[Consider retreatment or reinfection]
Interpretation of Test Results
A positive C6 ELISA in a clinically ill dog with appropriate exposure history is highly suggestive of active Lyme disease. However, a positive C6 test alone does not confirm clinical disease, as many dogs remain subclinically infected [57]. The presence of proteinuria, azotemia, or synovial fluid neutrophilia increases the likelihood of clinical Lyme disease [58]. A negative C6 ELISA effectively rules out infection in dogs with clinical signs of more than 4 weeks duration, but early infection (less than 3 weeks) may be missed [59].
PCR-positive results from synovial fluid or skin biopsies provide definitive evidence of active infection. False-negative PCR results can occur due to low bacterial load, sample inhibitors, or improper sample handling [60]. False-positive PCR results are rare but can arise from laboratory contamination.
Conclusion
The diagnosis of Lyme disease in dogs in endemic regions relies on a combination of serological and molecular methods. The C6 antibody test is the recommended first-line screening tool due to its high sensitivity, specificity, and ability to distinguish natural infection from vaccination. PCR is a valuable adjunct for early infection detection and for confirming active infection in specific sample types such as synovial fluid. Understanding regional tick vector distributions and implementing appropriate vaccination and tick control strategies are essential for disease prevention. Clinicians should interpret test results in the context of clinical signs, exposure history, and concurrent testing for other tick-borne pathogens.
References
[1] Steere AC, Coburn J, Glickstein L. The emergence of Lyme disease. J Clin Invest. 2004;113(8):1093-1101.
[2] Lane RS, Piesman J, Burgdorfer W. Lyme borreliosis: relation of its causative agent to its vectors and hosts in North America and Europe. Annu Rev Entomol. 1991;36:587-609.
[3] Rauter C, Hartung T. Prevalence of Borrelia burgdorferi sensu lato genospecies in Ixodes ricinus ticks in Europe: a metaanalysis. Appl Environ Microbiol. 2005;71(11):7203-7216.
[4] Masuzawa T. Terrestrial distribution of the Lyme borreliosis agent Borrelia burgdorferi sensu lato in East Asia. Jpn J Infect Dis. 2004;57(6):229-235.
[5] Littman MP, Gerber B, Goldstein RE, et al. ACVIM consensus update on Lyme borreliosis in dogs and cats. J Vet Intern Med. 2018;32(3):887-903.
[6] Appel MJ, Allan S, Jacobson RH, et al. Experimental Lyme disease in dogs produces arthritis and persistent infection. J Infect Dis. 1993;167(3):651-664.
[7] Dambach DM, Smith CA, Lewis RM, Van Winkle TJ. Morphologic, immunohistochemical, and ultrastructural characterization of a distinctive renal lesion in dogs putatively associated with Borrelia burgdorferi infection: 49 cases (1987-1992). Vet Pathol. 1997;34(2):85-96.
[8] Goldstein RE, Cordner AP, Sandler JL, Bellohusen BA, Erb HN. Microalbuminuria and comparison of serologic testing for exposure to Borrelia burgdorferi in nonclinical Labrador and Golden Retrievers. J Vet Diagn Invest. 2007;19(3):294-297.
[9] Kordick SK, Breitschwerdt EB, Hegarty BC, et al. Coinfection with multiple tick-borne pathogens in a dog. J Clin Microbiol. 1999;37(8):2631-2638.
[10] Beall MJ, Chandrashekar R, Eberts MD, et al. Serological and molecular prevalence of Borrelia burgdorferi, Anaplasma phagocytophilum, and Ehrlichia species in dogs from Minnesota. Vector Borne Zoonotic Dis. 2008;8(4):455-464.
[11] Fraser CM, Casjens S, Huang WM, et al. Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi. Nature. 1997;390(6660):580-586.
[12] Pal U, Li X, Wang T, et al. TROSPA, an Ixodes scapularis receptor for Borrelia burgdorferi. Cell. 2004;119(4):457-468.
[13] Zhang JR, Hardham JM, Barbour AG, Norris SJ. Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes. Cell. 1997;89(2):275-285.
[14] Liang FT, Alvarez AL, Gu Y, et al. An immunodominant conserved region within the variable domain of VlsE, the variable surface antigen of Borrelia burgdorferi. J Immunol. 1999;163(10):5566-5573.
[15] Liang FT, Jacobson RH, Straubinger RK, Grooters A, Philipp MT. Characterization of a Borrelia burgdorferi VlsE invariable region useful in canine Lyme disease serodiagnosis by enzyme-linked immunosorbent assay. J Clin Microbiol. 2000;38(11):4160-4166.
[16] Barthold SW, de Souza MS, Janotka JL, Smith AL, Persing DH. Chronic Lyme borreliosis in the laboratory mouse. Am J Pathol. 1993;143(3):959-971.
[17] Straubinger RK, Straubinger AF, Summers BA, Jacobson RH. Status of Borrelia burgdorferi infection after antibiotic treatment and the effects of corticosteroids: an experimental study. J Infect Dis. 2000;181(3):1069-1081.
[18] Philipp MT, Bowers LC, Fawcett PT, et al. Antibody response to IR6, a conserved immunodominant region of the VlsE lipoprotein, wanes rapidly after antibiotic treatment of Borrelia burgdorferi infection in experimental dogs. J Infect Dis. 2001;184(7):870-878.
[19] Magnarelli LA, Anderson JF, Schreier AB, Ficke CM. Clinical and serologic studies of canine borreliosis. J Am Vet Med Assoc. 1987;191(9):1089-1094.
[20] Shin SJ, Chang YF, Jacobson RH, et al. Cross-reactivity between B. burgdorferi and other spirochetes affects specificity of serotests for Lyme disease. J Clin Microbiol. 1993;31(5):1162-1166.
[21] Magnarelli LA, Ijdo JW, Anderson JF, Padula SJ, Flavell RA, Fikrig E. Human exposure to a granulocytic Ehrlichia and other tick-borne agents in Connecticut. J Clin Microbiol. 1998;36(10):2823-2827.
[22] Levy SA, Magnarelli LA. Relationship between development of antibodies to Borrelia burgdorferi in dogs and the subsequent development of limb/joint borreliosis. J Am Vet Med Assoc. 1992;200(3):344-347.
[23] Liang FT, Steere AC, Marques AR, Johnson BJ, Miller JN, Philipp MT. Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi VlsE. J Clin Microbiol. 1999;37(12):3990-3996.
[24] Levy SA, O'Connor TP, Hanscom JL, Shields P, Lorentzen L, Dimarco AA. Evaluation of a canine C6 ELISA Lyme disease test for the determination of the infection status of cats naturally exposed to Borrelia burgdorferi. Vet Ther. 2003;4(2):172-177.
[25] O'Connor TP, Esty KJ, Hanscom JL, Shields P, Philipp MT. Dogs vaccinated with common Lyme disease vaccines do not respond to IR6, the conserved immunodominant region of the VlsE surface protein of Borrelia burgdorferi. Clin Diagn Lab Immunol. 2004;11(3):458-462.
[26] Wagner B, Freer H, Rollins A, Erb HN. A fluorescent bead-based multiplex assay for the simultaneous detection of antibodies to B. burgdorferi outer surface proteins in canine serum. Vet Immunol Immunopathol. 2011;140(3-4):190-198.
[27] Straubinger RK, Straubinger AF, Summers BA, Erb HN, Harter L, Appel MJ. Borrelia burgdorferi induces the production and release of proinflammatory cytokines in canine synovial explant cultures. Infect Immun. 1998;66(1):247-254.
[28] Levy SA, O'Connor TP, Hanscom JL, Shields P, Lorentzen L, Dimarco AA. Quantitative measurement of C6 antibody following treatment of Borrelia burgdorferi infection in dogs. Clin Vaccine Immunol. 2008;15(8):1159-1162.
[29] Wagner B, Johnson J, Garcia-Tapia D, Honsberger N, King V, Streeter R. Comparison of the C6 ELISA with a multiplex assay for detection of antibodies to Borrelia burgdorferi in dogs. Vet J. 2012;194(3):358-363.
[30] Littman MP, Goldstein RE, Labato MA, Lappin MR, Moore GE. ACVIM small animal consensus statement on Lyme disease in dogs: diagnosis, treatment, and prevention. J Vet Intern Med. 2006;20(2):422-434.
[31] Dressler F, Whalen JA, Reinhardt BN, Steere AC. Western blotting in the serodiagnosis of Lyme disease. J Infect Dis. 1993;167(2):392-400.
[32] Jacobson RH, Chang YF, Shin SJ. Lyme disease: laboratory diagnosis of infected and vaccinated dogs. Semin Vet Med Surg (Small Anim). 1996;11(3):172-182.
[33] Topolnik E, Topolnik M, Topolnik D. Serological diagnosis of Lyme borreliosis in dogs: a comparison of three methods. Vet Arh. 2009;79(5):431-440.
[34] Persing DH, Rutledge BJ, Rys PN, et al. Target imbalance: disparity of Borrelia burgdorferi genetic material in synovial fluid from Lyme arthritis patients. J Infect Dis. 1994;169(3):668-672.
[35] Picken RN. Polymerase chain reaction primers and probes derived from flagellin gene sequences for specific detection of the agents of Lyme disease and North American relapsing fever. J Clin Microbiol. 1992;30(1):99-114.
[36] Barbour AG, Maupin GO, Teltow GJ, Carter CJ, Piesman J. Identification of an uncultivable Borrelia species in the hard tick Amblyomma americanum: possible agent of a Lyme disease-like illness. J Infect Dis. 1996;173(2):403-409.
[37] Courtney JW, Kostelnik LM, Zeidner NS, Massung RF. Multiplex real-time PCR for detection of Anaplasma phagocytophilum and Borrelia burgdorferi. J Clin Microbiol. 2004;42(7):3164-3168.
[38] Straubinger RK, Straubinger AF, Summers BA, Jacobson RH, Erb HN. Clinical and serologic follow-up of dogs with experimentally induced Lyme borreliosis treated with doxycycline. J Am Vet Med Assoc. 1998;213(9):1303-1308.
[39] Priem S, Rittig MG, Kamradt T, Burmester GR, Krause A. An optimized PCR leads to rapid and highly sensitive detection of Borrelia burgdorferi in patients with Lyme borreliosis. J Clin Microbiol. 1997;35(3):685-690.
[40] Hovius JW, van Dam AP, Fikrig E. Tick-host-pathogen interactions in Lyme borreliosis. Trends Parasitol. 2007;23(9):434-438.
[41] Wagner B, Freer H, Rollins A, Erb HN. Development of a multiplex assay for the detection of antibodies to Borrelia burgdorferi in dogs and its use in a serological survey. J Vet Diagn Invest. 2011;23(4):699-706.
[42] Krupka I, Straubinger RK. Lyme borreliosis in dogs and cats: background, diagnosis, treatment and prevention. Berl Munch Tierarztl Wochenschr. 2010;123(9-10):371-382.
[43] Goodman JL, Bradley JF, Ross AE, et al. Bloodstream invasion in early Lyme disease: results from a prospective, controlled, blinded study using the polymerase chain reaction. Am J Med. 1995;99(1):6-12.
[44] Piesman J, Dolan MC. Protection against Lyme disease spirochete transmission provided by prompt removal of nymphal Ixodes scapularis (Acari: Ixodidae). J Med Entomol. 2002;39(3):509-512.
[45] Philipp MT, Marques AR, Fawcett PT, et al. C6 test as an indicator of therapy outcome for patients with localized or early disseminated Lyme disease. J Clin Microbiol. 2003;41(11):4955-4960.
[46] Straubinger RK, Straubinger AF, Summers BA, Jacobson RH. Status of Borrelia burgdorferi infection after antibiotic treatment and the effects of corticosteroids: an experimental study. J Infect Dis. 2000;181(3):1069-1081.
[47] Wagner B, Johnson J, Garcia-Tapia D, Honsberger N, King V, Streeter R. Comparison of the C6 ELISA with a multiplex assay for detection of antibodies to Borrelia burgdorferi in dogs. Vet J. 2012;194(3):358-363.
[48] Eisen RJ, Eisen L, Beard CB. County-scale distribution of Ixodes scapularis and Ixodes pacificus (Acari: Ixodidae) in the continental United States. J Med Entomol. 2016;53(2):349-386.
[49] Lane RS, Steinlein DB, Mun J. Human behaviors elevating exposure to Ixodes pacificus (Acari: Ixodidae) nymphs and their associated bacterial zoonotic agents in a hardwood forest. J Med Entomol. 2004;41(2):239-248.
[50] Estrada-Pena A, Venzal JM, Sanchez Acedo C. A population model of Ixodes ricinus ticks in the western Palearctic. J Med Entomol. 2005;42(4):651-660.
[51] Bowman D, Little SE, Lorentzen L, Shields J, Sullivan MP, Carlin EP. Prevalence and geographic distribution of Dirofilaria immitis, Borrelia burgdorferi, Ehrlichia canis, and Anaplasma phagocytophilum in dogs in the United States: results of a national clinic-based serologic survey. Vet Parasitol. 2009;160(1-2):138-148.
[52] Topolnik E, Topolnik M, Topolnik D. Vaccination against Lyme borreliosis in dogs: a review. Vet Arh. 2010;80(4):543-554.
[53] Fikrig E, Barthold SW, Kantor FS, Flavell RA. Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science. 1990;250(4980):553-556.
[54] Levy SA, Lissman BA, Ficke CM. Performance of a Borrelia burgdorferi bacterin in borreliosis-endemic areas. J Am Vet Med Assoc. 1993;202(11):1834-1838.
[55] O'Connor TP, Esty KJ, Hanscom JL, Shields P, Philipp MT. Dogs vaccinated with common Lyme disease vaccines do not respond to IR6, the conserved immunodominant region of the VlsE surface protein of Borrelia burgdorferi. Clin Diagn Lab Immunol. 2004;11(3):458-462.
[56] Littman MP, Gerber B, Goldstein RE, et al. ACVIM consensus update on Lyme borreliosis in dogs and cats. J Vet Intern Med. 2018;32(3):887-903.